Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
Pont-Sunyer C, Tolosa E, Caspell-Garcia C, Coffey C, Alcalay RN, Chan P, Duda JE, Facheris M, Fernández-Santiago R, Marek K, Lomeña F, Marras C, Mondragon E, Saunders-Pullman R, Waro B; LRRK2 Cohort Consortium. Pont-Sunyer C, et al. Among authors: alcalay rn. Mov Disord. 2017 May;32(5):726-738. doi: 10.1002/mds.26964. Epub 2017 Mar 28. Mov Disord. 2017. PMID: 28370517
Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.
Clark LN, Kisselev S, Park N, Ross B, Verbitsky M, Rios E, Alcalay RN, Lee JH, Louis ED. Clark LN, et al. Among authors: alcalay rn. Parkinsonism Relat Disord. 2010 Feb;16(2):132-5. doi: 10.1016/j.parkreldis.2009.05.008. Epub 2009 Jun 13. Parkinsonism Relat Disord. 2010. PMID: 19527940 Free PMC article.
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Alcalay RN, et al. Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267. Arch Neurol. 2009. PMID: 20008657 Free PMC article.
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Alcalay RN, et al. J Clin Exp Neuropsychol. 2010 Aug;32(7):775-9. doi: 10.1080/13803390903521018. Epub 2010 Feb 24. J Clin Exp Neuropsychol. 2010. PMID: 20182943 Free PMC article.
Clinical and pathological characteristics of LRRK2 G2019S patients with PD.
Poulopoulos M, Cortes E, Vonsattel JP, Fahn S, Waters C, Cote LJ, Moskowitz C, Honig LS, Clark LN, Marder KS, Alcalay RN. Poulopoulos M, et al. Among authors: alcalay rn. J Mol Neurosci. 2012 May;47(1):139-43. doi: 10.1007/s12031-011-9696-y. Epub 2011 Dec 23. J Mol Neurosci. 2012. PMID: 22194196 Free PMC article.
The neuropathology of genetic Parkinson's disease.
Poulopoulos M, Levy OA, Alcalay RN. Poulopoulos M, et al. Among authors: alcalay rn. Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26. Mov Disord. 2012. PMID: 22451330 Free PMC article. Review.
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A, Mirelman A, Helmich RC, van Nuenen BF, Rosenberg-Katz K, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N, Hendler T; LRRK2 Ashkenazi Jewish consortium. Thaler A, et al. Cortex. 2013 Oct;49(9):2501-11. doi: 10.1016/j.cortex.2012.12.017. Epub 2013 Jan 7. Cortex. 2013. PMID: 23357204
Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, Bressman S, Bar-Shira A, Orr-Urtreger A, Giladi N, Hausdorff JM; LRRK2 Ashkenazi Jewish Consortium. Mirelman A, et al. Mov Disord. 2013 Oct;28(12):1683-90. doi: 10.1002/mds.25587. Epub 2013 Oct 7. Mov Disord. 2013. PMID: 24123150
227 results